OncLive articleshttps://www.onclive.com/newsOncLive articles© 2026 MJH Life Sciences™ and OncLive. All rights reserved.Wed, 08 Jul 2026 07:12:28 +00005en-us14447https://www.onclive.com/newshttps://www.onclive.com/logo.webphttps://www.onclive.com/view/domvanalimab-zimberelimab-plus-chemotherapy-fails-to-improve-os-in-her2-negative-gastroesophageal-adenocarcinomahttps://www.onclive.com/view/domvanalimab-zimberelimab-plus-chemotherapy-fails-to-improve-os-in-her2-negative-gastroesophageal-adenocarcinoma<![CDATA[First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.]]>Tue, 07 Jul 2026 23:25:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/extended-folfox-atezolizumab-duration-linked-with-improved-dfs-in-stage-iii-dmmr-colon-cancerhttps://www.onclive.com/view/extended-folfox-atezolizumab-duration-linked-with-improved-dfs-in-stage-iii-dmmr-colon-cancer<![CDATA[Longer duration of adjuvant FOLFOX and atezolizumab was associated with improved DFS in a retrospective analysis of the ATOMIC trial.]]>Tue, 07 Jul 2026 21:11:35 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/bexobrutideg-could-pave-the-way-for-btk-degraders-in-r-r-chronic-lymphocytic-leukemiahttps://www.onclive.com/view/bexobrutideg-could-pave-the-way-for-btk-degraders-in-r-r-chronic-lymphocytic-leukemia<![CDATA[Nirav N. Shah, MD, MSHP, discusses bexobrutideg and what the BTK degrader could bring to chronic lymphocytic leukemia management.]]>Tue, 07 Jul 2026 20:10:39 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/further-integrating-biosimilars-into-oncology-the-role-of-wyost-denosumab-bbdz-in-preventing-cancer-related-skeletal-events-with-bone-metastases-from-solid-tumorshttps://www.onclive.com/view/further-integrating-biosimilars-into-oncology-the-role-of-wyost-denosumab-bbdz-in-preventing-cancer-related-skeletal-events-with-bone-metastases-from-solid-tumors<![CDATA[Cancer patients facing skeletal-related events may benefit from WYOST®, the first FDA-approved biosimilar for this condition, offering safe, effective, and more affordable treatment for bone complications.]]>Tue, 07 Jul 2026 20:00:12 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-bekaii-saab-on-the-fda-approval-of-zenocutuzumab-in-nrg1-cholangiocarcinomahttps://www.onclive.com/view/dr-bekaii-saab-on-the-fda-approval-of-zenocutuzumab-in-nrg1-cholangiocarcinoma<![CDATA[Tanios S. Bekaii-Saab, MD, discusses the clinical significance of the FDA approval of zenocutuzumab for NRG1 fusion–positive CCA. ]]>Tue, 07 Jul 2026 19:42:14 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-shah-on-the-significance-of-daybreak-cll-201-and-bexobrutideg-for-the-cll-treatment-paradigmhttps://www.onclive.com/view/dr-shah-on-the-significance-of-daybreak-cll-201-and-bexobrutideg-for-the-cll-treatment-paradigm<![CDATA[Nirav N. Shah, MD, MSHP, discusses the design of DAYBreak CLL-201 and its potential importance for chronic lymphocytic leukemia management.]]>Tue, 07 Jul 2026 19:38:45 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/esr1-mutations-steer-the-oral-serd-story-in-breast-cancer-with-sara-nunnery-md-msci-and-minhtri-nguyen-mdhttps://www.onclive.com/view/esr1-mutations-steer-the-oral-serd-story-in-breast-cancer-with-sara-nunnery-md-msci-and-minhtri-nguyen-md<![CDATA[Drs Nunnery and Nguyen discuss the emergence of the oral SERD giredestrant in hormone receptor–positive, HER2-negative breast cancer management.]]>Tue, 07 Jul 2026 17:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dana-farber-investigators-report-promising-results-from-phase-2-study-of-targeted-therapy-for-rare-bile-duct-cancerhttps://www.onclive.com/view/dana-farber-investigators-report-promising-results-from-phase-2-study-of-targeted-therapy-for-rare-bile-duct-cancer<![CDATA[Promising data for zenocutuzumab in patients with advanced NRG1-positive cholangiocarcinoma were shown according to researchers at Dana-Farber.]]>Tue, 07 Jul 2026 16:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/medical-crossfire-precision-oncology-in-nsclc-translating-her2-and-trop2-innovation-into-practice-changing-carehttps://www.onclive.com/view/medical-crossfire-precision-oncology-in-nsclc-translating-her2-and-trop2-innovation-into-practice-changing-care<![CDATA[OncLive On Air® CE]]>Tue, 07 Jul 2026 15:48:30 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/ai-finds-new-applications-in-oncologic-surgery-drug-and-biomarker-screening-and-clinical-trial-designhttps://www.onclive.com/view/ai-finds-new-applications-in-oncologic-surgery-drug-and-biomarker-screening-and-clinical-trial-design<![CDATA[OncLive spoke with expert investigators to gather insights on the role of AI in cancer care, including oncologic surgery and drug development. ]]>Tue, 07 Jul 2026 14:05:04 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-spencer-on-early-efficacy-data-for-in-vivo-car-t-cell-therapy-in-r-r-myelomahttps://www.onclive.com/view/dr-spencer-on-early-efficacy-data-for-in-vivo-car-t-cell-therapy-in-r-r-myeloma<![CDATA[Andrew Spencer, MBBS, FRACP, FRCPA, DM, discusses efficacy data for the in vivo CAR T-cell therapy KLN-1010 in multiple myeloma.]]>Tue, 07 Jul 2026 14:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/adagrasib-plus-cetuximab-misses-os-pfs-end-points-in-pretreated-kras-g12c-mutated-crchttps://www.onclive.com/view/adagrasib-plus-cetuximab-misses-os-pfs-end-points-in-pretreated-kras-g12c-mutated-crc<![CDATA[Adagrasib in combination with cetuximab did not significantly improve OS or PFS in KRAS G12C–mutated metastatic colorectal cancer.]]>Tue, 07 Jul 2026 13:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/hr-positive-her2-negative-metastatic-breast-cancer-molecular-testing-and-targeted-therapy-selection-after-disease-progressionhttps://www.onclive.com/view/hr-positive-her2-negative-metastatic-breast-cancer-molecular-testing-and-targeted-therapy-selection-after-disease-progression<![CDATA[Dr. Adam Brufsky and the panel continue their discussion of treatment sequencing in HR-positive/HER2-negative metastatic breast cancer, focusing on the role of molecular profiling and biomarker-directed therapy following progression on CDK4/6 inhibitor-based treatment. ]]>Tue, 07 Jul 2026 12:15:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/adcs-in-cns-disease-and-managing-patients-with-multiple-biomarkershttps://www.onclive.com/view/adcs-in-cns-disease-and-managing-patients-with-multiple-biomarkers<![CDATA[The panel addresses one of the more difficult challenges in metastatic TNBC: central nervous system involvement.]]>Tue, 07 Jul 2026 12:10:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/the-case-for-first-line-therapy-and-understanding-trop2-as-a-targethttps://www.onclive.com/view/the-case-for-first-line-therapy-and-understanding-trop2-as-a-target<![CDATA[The panel discusses the rationale for using effective agents in the first-line metastatic setting rather than reserving them for later lines, considering the disease's aggressive course and limited expected survival alongside the trajectories seen in other breast cancer subtypes.]]>Tue, 07 Jul 2026 12:05:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/early-treatment-access-and-palliative-care-integration-for-patients-with-es-sclchttps://www.onclive.com/view/early-treatment-access-and-palliative-care-integration-for-patients-with-es-sclc<![CDATA[Dr. Sands argues that successful second-line agents should move earlier in treatment sequencing, citing precedent from other oncology fields. With only 40% to 50% of patients with ES-SCLC receiving second-line therapy due to rapid disease progression, declining functional status, or brain metastases, moving effective agents like tarlatamab earlier addresses this attrition problem.]]>Tue, 07 Jul 2026 12:05:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/os-benefit-patient-communication-and-frontline-risk-in-dlbclhttps://www.onclive.com/view/os-benefit-patient-communication-and-frontline-risk-in-dlbcl<![CDATA[Dr. Graff addresses whether the absence of overall survival benefit from either POLARIX or frontMIND should discourage adoption.]]>Tue, 07 Jul 2026 12:05:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/safety-tolerability-and-mechanism-of-duvelisibhttps://www.onclive.com/view/safety-tolerability-and-mechanism-of-duvelisib<![CDATA[Zinzani and Brammer turn to the safety profile and mechanism of duvelisib, addressing concerns that have historically accompanied PI3K inhibition. Zinzani notes that contemporary management has improved markedly, with reduced rates of colitis, transaminitis, and pulmonary toxicity, few high-grade events, and a generally manageable profile aided by the induction-then-reduction dosing strategy. Brammer explains the mechanistic basis for duvelisib's distinctive activity, describing it as an inhibitor of both the delta and gamma isoforms of PI3K. He notes that delta inhibition acts on tumor growth and proliferation, while gamma inhibition disrupts the immunosuppressive tumor microenvironment, an effect especially relevant in T-follicular helper disease, where the malignant cells are themselves immune cells prone to autoimmune-type manifestations. ]]>Tue, 07 Jul 2026 12:05:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/phase-1-data-highlight-potential-utility-for-in-vivo-car-t-cell-therapy-in-r-r-myelomahttps://www.onclive.com/view/phase-1-data-highlight-potential-utility-for-in-vivo-car-t-cell-therapy-in-r-r-myeloma<![CDATA[Andrew Spencer, MBBS, FRACP, FRCPA, DM, breaks down phase 1 data for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.]]>Tue, 07 Jul 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/choosing-between-two-frontline-regimens-in-dlbclhttps://www.onclive.com/view/choosing-between-two-frontline-regimens-in-dlbcl<![CDATA[Dr. Lunning discusses decision-making when both Pola-R-CHP and Tafa-Len-R-CHOP are options.]]>Tue, 07 Jul 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/clinical-scenario-cns-only-progression-on-osimertinib-in-egfr-mutated-nsclchttps://www.onclive.com/view/clinical-scenario-cns-only-progression-on-osimertinib-in-egfr-mutated-nsclc<![CDATA[Dr. Nagpal presents a 58-year-old female non-smoker with stage IVB lung adenocarcinoma, EGFR L858R mutation, and TP53 co-mutation who maintained partial systemic response on first-line osimertinib for approximately 3.5 years.]]>Tue, 07 Jul 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/nccn-guideline-updates-and-choosing-a-first-line-adchttps://www.onclive.com/view/nccn-guideline-updates-and-choosing-a-first-line-adc<![CDATA[The panel reviews how the metastatic TNBC treatment paradigm has evolved, tracing TROP2-directed ADCs from later-line use into the first-line setting.]]>Tue, 07 Jul 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/limitations-of-phase-1b-data-and-biomarker-development-in-es-sclchttps://www.onclive.com/view/limitations-of-phase-1b-data-and-biomarker-development-in-es-sclc<![CDATA[Dr. Shields addresses limitations of phase 1b single-arm studies, noting smaller patient numbers may introduce selection bias toward patients most likely to benefit from T-cell engager therapy targeting DLL3 and CD3. She emphasizes the importance of randomized phase 3 data for head-to-head comparisons, particularly given that DeLLphi-303's control arm involved immunotherapy alone, preventing cross-trial comparisons with IMforte's different control arm.]]>Tue, 07 Jul 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/primo-trial-design-and-efficacy-in-relapsed-refractory-ptclhttps://www.onclive.com/view/primo-trial-design-and-efficacy-in-relapsed-refractory-ptcl<![CDATA[Zinzani details the design and outcomes of the PRIMO study, an international evaluation of duvelisib in relapsed or refractory peripheral T-cell lymphoma that enrolled a substantial cohort weighted toward the most common histologic subtypes.]]>Tue, 07 Jul 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/hr-positive-her2-negative-metastatic-breast-cancer-sequencing-strategies-after-cdk4-6-inhibitor-progressionhttps://www.onclive.com/view/hr-positive-her2-negative-metastatic-breast-cancer-sequencing-strategies-after-cdk4-6-inhibitor-progression<![CDATA[Dr. Adam Brufsky and the panel examine treatment decision-making following progression on first-line CDK4/6 inhibitor-based therapy in patients with HR-positive/HER2-negative metastatic breast cancer.]]>Tue, 07 Jul 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-spencer-on-differentiating-factors-for-in-vivo-car-t-cell-therapy-in-myelomahttps://www.onclive.com/view/dr-spencer-on-differentiating-factors-for-in-vivo-car-t-cell-therapy-in-myeloma<![CDATA[Andrew Spencer, MBBS, FRACP, FRCPA, DM, discusses key features of in vivo CAR T-cell therapy in multiple myeloma.]]>Mon, 06 Jul 2026 21:28:14 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/fda-issues-crl-to-orviglance-for-liver-metastasis-imaging-in-patients-with-severe-kidney-impairmenthttps://www.onclive.com/view/fda-issues-crl-to-orviglance-for-liver-metastasis-imaging-in-patients-with-severe-kidney-impairment<![CDATA[The FDA gave a CRL to the NDA seeking the approval of Orviglance for use in the detection of liver metastases in patients with severe kidney impairment.]]>Mon, 06 Jul 2026 20:40:26 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/epcoritamab-plus-lenalidomide-rituximab-win-eu-approval-for-r-r-follicular-lymphomahttps://www.onclive.com/view/epcoritamab-plus-lenalidomide-rituximab-win-eu-approval-for-r-r-follicular-lymphoma<![CDATA[The European Commission has approved epcoritamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma.]]>Mon, 06 Jul 2026 20:24:32 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-bose-on-the-rationale-for-evaluating-sapablursen-in-polycythemia-verahttps://www.onclive.com/view/dr-bose-on-the-rationale-for-evaluating-sapablursen-in-polycythemia-vera<![CDATA[Prithviraj Bose, MD, discusses the ongoing investigation of sapablursen in polycythemia vera.]]>Mon, 06 Jul 2026 19:27:13 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-rao-on-the-prognostic-value-of-post-surgical-ctdna-status-in-early-tnbchttps://www.onclive.com/view/dr-rao-on-the-prognostic-value-of-post-surgical-ctdna-status-in-early-tnbc<![CDATA[Ruta D. Rao, MD, discusses a prospective sub-study of the PARTNER trial evaluating the effect of ctDNA status on distant recurrence in early TNBC.]]>Mon, 06 Jul 2026 17:00:00 GMTOncLiveusOncLive Articles